Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 442Stomach Neoplasms 290Rectal Neoplasms 266Colonic Neoplasms 191Pancreatic Neoplasms 175Neoplasm Metastasis 110Esophageal Neoplasms 87Neoplasms 68Carcinoma, Hepatocellular 59Adenocarcinoma Of Esophagus 47Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Cholangiocarcinoma 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 37Gallbladder Neoplasms 30Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 24Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 17Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Urothelial Cancer × Oxaliplatin × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡